Hims & Hers Health (NYSE:HIMS) Hits New 12-Month High – Time to Buy?

Shares of Hims & Hers Health, Inc. (NYSE:HIMSGet Free Report) reached a new 52-week high on Friday . The stock traded as high as $35.78 and last traded at $36.18, with a volume of 3398214 shares traded. The stock had previously closed at $33.96.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Piper Sandler raised their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research note on Monday, January 6th. BTIG Research started coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Deutsche Bank Aktiengesellschaft raised their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Morgan Stanley initiated coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price for the company. Finally, Needham & Company LLC upped their price objective on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $25.13.

Check Out Our Latest Stock Report on HIMS

Hims & Hers Health Stock Up 10.8 %

The company has a market capitalization of $8.22 billion, a price-to-earnings ratio of 84.57 and a beta of 1.31. The stock has a fifty day moving average price of $28.96 and a two-hundred day moving average price of $22.47.

Hims & Hers Health (NYSE:HIMSGet Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter last year, the firm earned ($0.04) earnings per share. The business’s revenue was up 77.1% on a year-over-year basis. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 2,343 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $29.90, for a total transaction of $70,055.70. Following the sale, the insider now directly owns 165,254 shares of the company’s stock, valued at $4,941,094.60. The trade was a 1.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the transaction, the chief executive officer now directly owns 67,015 shares in the company, valued at $1,399,273.20. The trade was a 73.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,256,067 shares of company stock worth $34,459,485. Insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Crewe Advisors LLC bought a new stake in shares of Hims & Hers Health in the 4th quarter valued at approximately $28,000. Raleigh Capital Management Inc. raised its stake in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares in the last quarter. GAMMA Investing LLC grew its stake in Hims & Hers Health by 2,173.7% during the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after buying an additional 2,152 shares during the last quarter. Principal Securities Inc. increased its holdings in shares of Hims & Hers Health by 48.2% during the fourth quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock worth $74,000 after buying an additional 1,002 shares in the last quarter. Finally, Quest Partners LLC boosted its holdings in shares of Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after acquiring an additional 807 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Featured Stories

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.